MT-125 and Sutent synergize to attack brain tumors (IMAGE)
Caption
Mice engineered to develop brain tumors were treated with MT-125 alone and MT-125 plus a chemotherapy drug called suntinib. After four weeks, the mice treated with the drug combo showed a dramatic reduction in the tumors.
Credit
Image courtesy Steven Rosenfeld, M.D., Ph.D., and Courtney Miller, Ph.D.
Usage Restrictions
For use with coverage of research from Courtney Miller, Ph.D., at The Wertheim UF Scripps Institute and Steven Rosenfeld, M.D., Ph.D.
License
Original content